A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer - Wikidata - awgldk - TriplyDB

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

http://www.wikidata.org/entity/Q34775850

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment The antitumor activity screening of chemical constituents from Camellia nitidissima Chi.

P2860

Q26769884-D5EDD224-8A7B-4CBB-B880-26C914836CA7 Q28069424-26850C91-9C95-4ED5-9315-EB2DBBFF4AF4 Q52684066-05F6E6B9-3BBF-421F-9B82-F4B7D74EA199

P2860

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

http://www.wikidata.org/entity/Q34775850

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@ast

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@en

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@nl

type

label

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@ast

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@en

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@nl

prefLabel

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@ast

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@en

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@nl

P1433

Q34775850-82905A98-0E9D-434C-961F-F9F8D019A836

P1476

Q34775850-69559B1D-5551-456F-82F9-71834E8A6B33

P2093

Q34775850-4124C459-9C09-4DB9-9E56-3D33B7BE30B1

Q34775850-4BFED947-DED5-4B27-B959-9A5DE4154FA0

Q34775850-4DBF798F-B52C-4F7D-80E3-9DEC5609F098

Q34775850-51BED526-05D0-4536-A056-4CECF38A850D

Q34775850-57A460DA-3810-4097-8EDF-E1A01C8088B1

Q34775850-97FC537C-6A55-4555-8D49-EA7A593DE881

Q34775850-CD8DF59C-0FBD-4CB2-A833-60FF8980765C

Q34775850-F797F9AB-A0EC-429F-8A47-75D1F4939F8A

P2860

Q34775850-0976D334-52C4-4B1A-A1C9-55440E9BF63F

Q34775850-1A15C936-95F0-4720-A1AE-DE773BABFDF3

Q34775850-1C8404D3-AAAF-462A-9E27-FA4831AFDCB4

Q34775850-2CA157BC-FB9D-4BF4-8890-1C05FCCD0290

Q34775850-32A5F03B-C42D-43BE-8BBC-E08CE06A16E4

Q34775850-36A69B85-05D5-4B11-9965-493159040E51

Q34775850-433AE355-DB36-4095-922F-2F1D99855D12

Q34775850-455C0169-8FF4-4E2F-BCF1-FDEF8D90B5F1

Q34775850-4C8069BD-B534-4E0F-9F0C-295DFC475BD8

Q34775850-4FEBD7CF-8E57-47AD-964A-49BA67351C46

P304

Q34775850-5F24B192-E89A-4989-B838-2121C828D22C

P31

Q34775850-FA879FF0-B0BD-4721-BEB1-D0970479EA73

P356

Q34775850-B24D53C3-510D-4E30-A9A7-5F41194E8C91

P433

Q34775850-FBF15E0F-F4FF-45AF-9E1E-EC19B27AAA1F

P478

Q34775850-D1F9CB8B-2B1D-48D7-BD8C-43AC5F7221BE

P577

Q34775850-3886A5F6-7AAA-4A53-B373-1AC28202EFF7

P5875

Q34775850-D8696A9F-F2E9-4063-BA2F-801D53FDE443

P698

Q34775850-E6A0F597-F269-44C1-B333-B38388C7F93D

P932

Q34775850-108B8E41-3D5D-44AC-8D95-B58194598560

P356

P1433

International Journal of Oncology

P1476

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

@en

P2093

Kazuya Ofuji

http://www.w3.org/2001/XMLSchema#string

Keigo Saito

http://www.w3.org/2001/XMLSchema#string

Manami Shimomura

http://www.w3.org/2001/XMLSchema#string

Mayuko Yoshimura

http://www.w3.org/2001/XMLSchema#string

Tetsuya Nakatsura

http://www.w3.org/2001/XMLSchema#string

Toshiaki Yoshikawa

http://www.w3.org/2001/XMLSchema#string

Yasunari Nakamoto

http://www.w3.org/2001/XMLSchema#string

Yoshitaka Tada

http://www.w3.org/2001/XMLSchema#string

P2860

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

Cancer immunotherapy: moving beyond current vaccines

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Cancer statistics, 2007

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

ERBB receptors and cancer: the complexity of targeted inhibitors

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

P304

497-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJO.2014.2787

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269933421

http://www.w3.org/2001/XMLSchema#string

P698

25532027

http://www.w3.org/2001/XMLSchema#string

P932

4277252

http://www.w3.org/2001/XMLSchema#string